Clinical Trials Logo

Filter by:
  • Withdrawn  
  • Page [1] ·  Next »
NCT ID: NCT06045624 Withdrawn - Alopecia Areata Clinical Trials

A First in Human Single and Multiple Ascending Dose and Open Label Food Effect Study of OR-101 in Healthy Subjects

Start date: October 17, 2023
Phase: Phase 1
Study type: Interventional

This first in human phase 1 study to Study will evaluate safety, tolerability, and pharmacokinetics of Single Ascending dose (SAD), Food effect (FE) and Multiple ascending dose (MAD) of OR-101 Administered Orally in healthy subjects

NCT ID: NCT06006416 Withdrawn - Gut Microbiome Clinical Trials

Effect of Fenugreek Fibre on Gut Microbiome

Start date: September 1, 2023
Phase: Phase 3
Study type: Interventional

A open label, self-controlled trial to evaluate the effect of Fenugreek Fibre (Trigonella foenum-graecum) on the gut microbiome in generally healthy adults aged 18-65 years old.

NCT ID: NCT05927012 Withdrawn - Clinical trials for Iron Deficiency Anemia

A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).

Start date: November 30, 2023
Phase: Phase 2
Study type: Interventional

This study aims to explore the safety and preliminary efficacy of a response-guided dose titration of KER-047 in the treatment of functional IDA (Iron deficiency anemia) in MDS (Myelodysplastic syndrome), MF(Myelofibrosis), and MDS/MPN (Myeloproliferative neoplasm) overlap syndromes.

NCT ID: NCT05572463 Withdrawn - Clinical trials for Metastatic Cutaneous Melanoma

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Start date: November 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a platform study evaluating the safety and efficacy of multiple novel investigational products (IPs) that target unresectable or metastatic cutaneous melanoma in participants who have failed standard treatment.

NCT ID: NCT05543356 Withdrawn - COVID-19 Clinical Trials

COVID-19 Fourth Dose Study in Australia

Start date: May 2, 2022
Phase: Phase 3
Study type: Interventional

This clinical trial will be a blinded, randomised study to determine the safety, reactogenicity, and immunogenicity of a second booster dose of SARS-CoV-2 vaccines in adults enrolled over two consecutive stages. Stage 1 will commence at the time of study approval and transition to stage 2 once bivalent vaccines are approved and available in Australia.

NCT ID: NCT05456269 Withdrawn - Clinical trials for Acute Myeloid Leukemia

A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS

BISECT
Start date: July 29, 2022
Phase: Phase 1
Study type: Interventional

This is a two strata Phase 1b study to assess the safety and efficacy of bisantrene (RC110) in combination with a) cytarabine arabinoside (Ara-C) treatment for patients with relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) with extramedullary disease and able to tolerate intensive chemotherapy; b) in combination with decitabine/cedazuridune (ASTX727) new or relapsed or refractory AML or high risk MDS or CMML with extramedullary disease and unable or not willing to have intensive chemotherapy.

NCT ID: NCT05441930 Withdrawn - Cataract Clinical Trials

A Study of Levofloxacin Ocular Implant in Patients Undergoing Routine Bilateral Cataract Surgery

Start date: June 23, 2023
Phase: Phase 1
Study type: Interventional

Open label controlled interventional study in eyes in up to 12 subjects (24 eyes) scheduled for uncomplicated bilateral cataract surgery on separate days.

NCT ID: NCT05332678 Withdrawn - Alzheimer's Disease Clinical Trials

SLS-005 (Trehalose Injection) in the Treatment of Alzheimer's Disease

[STRIVE-AD]
Start date: March 3, 2023
Phase: Phase 2
Study type: Interventional

An open-label, proof-of-concept study to evaluate the safety and treatment effects of SLS-005 in Participants with Alzheimer's Disease (AD) treated once or twice weekly for 52 weeks.

NCT ID: NCT05212922 Withdrawn - HCC Clinical Trials

A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC

YH001
Start date: June 2023
Phase: Phase 2
Study type: Interventional

This is an Open-label, Non-Randomized, Multi-center Phase 2 study of YH001 in Combination with Toripalimab,The study is designed to determine the safety ,tolerability and antitumor activity of YH001 in combination with Toripalimab in subjects with advanced NSCLC and HCC.

NCT ID: NCT05184101 Withdrawn - COVID-19 Clinical Trials

Inhaled Heparin for Hospitalised Patients With Coronavirus Disease 2019 (COVID-19)

INHALE-HEP
Start date: August 2023
Phase: Phase 2/Phase 3
Study type: Interventional

Investigator-initiated, multi-centre, randomised, open-label trial of nebulised heparin sodium in addition to standard care compared to standard care alone in hospitalised patients with COVID-19 infection.